Thank you for visiting Disc HQ in Watertown, BiotechTV! Brad and CEO John Quisel discuss positive clinical data across all three programs from #EHA2024, including bitopertin for #EPP, DISC-0974 for #anemia of myelofibrosis, and DISC-3405 in healthy volunteers. Full conversation below: https://lnkd.in/eV3_wJ2D
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Disc Medicine's CEO John Quisel reviews recent EHA data, including learnings about clinical endpoints from the company's lead GlyT1 program. He describes how bitopertin aims to reduce PPIX, a photosensitiser that makes it painful for patients when exposed to light. Plus, learnings about clinical endpoints from the company's P2 experience, and highlights on two hepcidin programs. Full video: https://lnkd.in/gAeE5uUc BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent